{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T23:41:04Z","timestamp":1787701264244,"version":"build-2784847793"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T00:00:00Z","timestamp":1701216000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T00:00:00Z","timestamp":1701216000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007229","name":"Bijzonder Onderzoeksfonds UGent","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007229","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["132118N"],"award-info":[{"award-number":["132118N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Methusalem"},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["CYRE, 340941"],"award-info":[{"award-number":["CYRE, 340941"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Despite major improvements in immunotherapeutic strategies, the immunosuppressive tumor microenvironment remains a major obstacle for the induction of efficient antitumor responses. In this study, we show that local delivery of a bispecific Clec9A-PD-L1 targeted type I interferon (AcTaferon, AFN) overcomes this hurdle by reshaping the tumor immune landscape.<\/jats:p><jats:p>Treatment with the bispecific AFN resulted in the presence of pro-immunogenic tumor-associated macrophages and neutrophils, increased motility and maturation profile of cDC1 and presence of inflammatory cDC2. Moreover, we report empowered diversity in the CD8<jats:sup>+<\/jats:sup> T cell repertoire and induction of a shift from naive, dysfunctional CD8<jats:sup>+<\/jats:sup> T cells towards effector, plastic cytotoxic T lymphocytes together with increased presence of NK and NKT cells as well as decreased regulatory T cell levels. These dynamic changes were associated with potent antitumor activity. Tumor clearance and immunological memory, therapeutic immunity on large established tumors and blunted tumor growth at distant sites were obtained upon co-administration of a non-curative dose of chemotherapy.<\/jats:p><jats:p>Overall, this study illuminates further application of type I interferon as a safe and efficient way to reshape the suppressive tumor microenvironment and induce potent antitumor immunity; features which are of major importance in overcoming the development of metastases and tumor cell resistance to immune attack. The strategy described here has potential for application across to a broad range of cancer types.<\/jats:p>","DOI":"10.1186\/s12943-023-01908-6","type":"journal-article","created":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T10:02:34Z","timestamp":1701252154000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["A bispecific Clec9A-PD-L1 targeted type I interferon profoundly reshapes the tumor microenvironment towards an antitumor state"],"prefix":"10.1186","volume":"22","author":[{"given":"Sandra","family":"Van Lint","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Van Parys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bram","family":"Van Den Eeckhout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"Vandamme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephane","family":"Plaisance","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annick","family":"Verhee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominiek","family":"Catteeuw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elke","family":"Rogge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"De Geest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nele","family":"Vanderroost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Roels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvan","family":"Saeys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Uz\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niko","family":"Kley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anje","family":"Cauwels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Tavernier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,29]]},"reference":[{"key":"1908_CR1","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1111\/j.1600-065X.2006.00442.x","volume":"213","author":"TF Gajewski","year":"2006","unstructured":"Gajewski TF, et al. Immune resistance orchestrated by the tumor microenvironment. Immunol Rev. 2006;213:131\u201345.","journal-title":"Immunol Rev"},{"key":"1908_CR2","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1111\/j.1440-1711.2005.01371.x","volume":"83","author":"A Pinzon-Charry","year":"2005","unstructured":"Pinzon-Charry A, Maxwell T, L\u00f3pez JA. Dendritic cell dysfunction in cancer: a mechanism for immunosuppression. Immunol Cell Biol. 2005;83:451\u201361.","journal-title":"Immunol Cell Biol"},{"key":"1908_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.coi.2015.10.009","volume":"39","author":"DH Munn","year":"2016","unstructured":"Munn DH, Bronte V. Immune suppressive mechanisms in the tumor microenvironment. Curr Opin Immunol. 2016;39:1\u20136.","journal-title":"Curr Opin Immunol"},{"key":"1908_CR4","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.ccell.2018.03.012","volume":"33","author":"DS Thommen","year":"2018","unstructured":"Thommen DS, Schumacher TN. T Cell dysfunction in cancer. Cancer Cell. 2018;33:547\u201362.","journal-title":"Cancer Cell"},{"key":"1908_CR5","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s12072-018-9867-9","volume":"12","author":"A Riva","year":"2018","unstructured":"Riva A, Chokshi S. Immune checkpoint receptors: homeostatic regulators of immunity. Hepatol Int. 2018;12:223\u201336.","journal-title":"Hepatol Int"},{"key":"1908_CR6","doi-asserted-by":"publisher","first-page":"e1314424","DOI":"10.1080\/2162402X.2017.1314424","volume":"6","author":"M Musella","year":"2017","unstructured":"Musella M, Manic G, De Maria R, Vitale I, Sistigu A. Type-I-interferons in infection and cancer: unanticipated dynamics with therapeutic implications. Oncoimmunology. 2017;6:e1314424.","journal-title":"Oncoimmunology"},{"key":"1908_CR7","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/nri3845","volume":"15","author":"L Zitvogel","year":"2015","unstructured":"Zitvogel L, Galluzzi L, Kepp O, Smyth MJ, Kroemer G. Type I interferons in anticancer immunity. Nat Rev Immunol. 2015;15:405\u201314.","journal-title":"Nat Rev Immunol"},{"key":"1908_CR8","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1634\/theoncologist.6-1-34","volume":"6","author":"E Jonasch","year":"2001","unstructured":"Jonasch E, Haluska FG. Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncologist. 2001;6:34\u201355.","journal-title":"Oncologist"},{"key":"1908_CR9","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.1038\/ncomms4016","volume":"5","author":"G Garcin","year":"2014","unstructured":"Garcin G, et al. High efficiency cell-specific targeting of cytokine activity. Nat Commun. 2014;5:3016.","journal-title":"Nat Commun"},{"key":"1908_CR10","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1158\/0008-5472.CAN-17-1980","volume":"78","author":"A Cauwels","year":"2018","unstructured":"Cauwels A, et al. Delivering type I interferon to dendritic cells empowers tumor eradication and immune combination treatments. Cancer Res. 2018;78:463\u201374.","journal-title":"Cancer Res"},{"key":"1908_CR11","doi-asserted-by":"publisher","first-page":"e1398876","DOI":"10.1080\/2162402X.2017.1398876","volume":"7","author":"A Cauwels","year":"2018","unstructured":"Cauwels A, et al. A safe and highly efficient tumor-targeted type I interferon immunotherapy depends on the tumor microenvironment. Oncoimmunology. 2018;7:e1398876.","journal-title":"Oncoimmunology"},{"issue":"2","key":"1908_CR12","doi-asserted-by":"publisher","first-page":"e11223","DOI":"10.15252\/emmm.201911223","volume":"12","author":"L Huyghe","year":"2020","unstructured":"Huyghe L, et al. Safe eradication of large established tumors using neovasculature-targeted tumor necrosis factor-based therapies. EMBO Mol Med. 2020;12(2):e11223.","journal-title":"EMBO Mol Med"},{"key":"1908_CR13","doi-asserted-by":"publisher","first-page":"e003293","DOI":"10.1136\/jitc-2021-003293","volume":"9","author":"Bram Van Den Eeckhout","year":"2021","unstructured":"Van Den EB, et al. Selective IL-1 activity on CD8+ T cells empowers antitumor immunity and synergizes with neovasculature-targeted TNF for full tumor eradication. J Immunother Cancer. 2021;9:e003293.","journal-title":"J Immunother Cancer"},{"key":"1908_CR14","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jaut.2018.10.010","volume":"97","author":"A Cauwels","year":"2019","unstructured":"Cauwels A, et al. Targeting interferon activity to dendritic cells enables in vivo tolerization and protection against EAE in mice. J Autoimmun. 2019;97:70\u20136.","journal-title":"J Autoimmun"},{"key":"1908_CR15","doi-asserted-by":"publisher","first-page":"21575","DOI":"10.1038\/s41598-021-00891-6","volume":"11","author":"A Cauwels","year":"2021","unstructured":"Cauwels A, et al. Targeting IFN activity to both B cells and plasmacytoid dendritic cells induces a robust tolerogenic response and protection against EAE. Sci Rep. 2021;11:21575.","journal-title":"Sci Rep"},{"key":"1908_CR16","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41541-020-00211-5","volume":"5","author":"B Van Den Eeckhout","year":"2020","unstructured":"Van Den Eeckhout B, et al. Specific Targeting of IL-1b activity to CD8+ T cells allows for safe use as a vaccine adjuvant. NPJ Vaccines. 2020;5:22.","journal-title":"NPJ Vaccines"},{"key":"1908_CR17","doi-asserted-by":"publisher","first-page":"6052","DOI":"10.1182\/blood-2012-01-406967","volume":"119","author":"LF Poulin","year":"2012","unstructured":"Poulin LF, et al. DNGR-1 is a specific and universal marker of mouse and human Batf3-dependent dendritic cells in lymphoid and nonlymphoid tissues. Blood. 2012;119:6052\u201362.","journal-title":"Blood"},{"key":"1908_CR18","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1038\/s41591-018-0085-8","volume":"24","author":"KC Barry","year":"2018","unstructured":"Barry KC, et al. A natural killer\u2013dendritic cell axis defines checkpoint therapy\u2013responsive tumor microenvironments. Nat Med. 2018;24:1178\u201391.","journal-title":"Nat Med"},{"key":"1908_CR19","doi-asserted-by":"publisher","first-page":"4828","DOI":"10.1200\/JCO.2011.38.0899","volume":"29","author":"SL Topalian","year":"2011","unstructured":"Topalian SL, Weiner GJ, Pardoll DM. Cancer immunotherapy comes of age. J Clin Oncol. 2011;29:4828\u201336.","journal-title":"J Clin Oncol"},{"key":"1908_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","volume":"39","author":"DS Chen","year":"2013","unstructured":"Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39:1\u201310.","journal-title":"Immunity"},{"key":"1908_CR21","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1023\/A:1006140513233","volume":"17","author":"JJ Killion","year":"1998","unstructured":"Killion JJ, Radinsky R, Fidler IJ. Orthotopic models are necessary to predict therapy of transplantable tumors in mice. Cancer Metastasis Rev. 1998;17:279\u201384.","journal-title":"Cancer Metastasis Rev"},{"issue":"6","key":"1908_CR22","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/j.immuni.2020.04.005","volume":"52","author":"C Bosteels","year":"2020","unstructured":"Bosteels C, et al. Inflammatory type 2 cDCs acquire features of cDC1s and macrophages to orchestrate immunity to respiratory virus infection. Immunity. 2020;52(6):1039\u201356.","journal-title":"Immunity"},{"key":"1908_CR23","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/nature01322","volume":"420","author":"LM Coussens","year":"2002","unstructured":"Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860\u20137.","journal-title":"Nature"},{"key":"1908_CR24","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1146\/annurev.immunol.021908.132532","volume":"27","author":"FO Martinez","year":"2009","unstructured":"Martinez FO, Helming L, Gordon S. Alternative activation of macrophages: an immunologic functional perspective. Annu Rev Immunol. 2009;27:451\u201383.","journal-title":"Annu Rev Immunol"},{"key":"1908_CR25","doi-asserted-by":"publisher","first-page":"5728","DOI":"10.1158\/0008-5472.CAN-09-4672","volume":"70","author":"K Movahedi","year":"2010","unstructured":"Movahedi K, et al. Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res. 2010;70:5728\u201339.","journal-title":"Cancer Res"},{"key":"1908_CR26","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3389\/fimmu.2019.00009","volume":"10","author":"J-C Cancel","year":"2019","unstructured":"Cancel J-C, Crozat K, Dalod M, Mattiuz R. Are conventional type 1 dendritic cells critical for protective antitumor immunity and how? Front Immunol. 2019;10:9.","journal-title":"Front Immunol"},{"key":"1908_CR27","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.immuni.2016.07.011","volume":"45","author":"A Schietinger","year":"2016","unstructured":"Schietinger A, et al. Tumor-specific T cell dysfunction is a dynamic antigen-driven differentiation program initiated early during tumorigenesis. Immunity. 2016;45:389\u2013401.","journal-title":"Immunity"},{"key":"1908_CR28","doi-asserted-by":"publisher","first-page":"8509","DOI":"10.1002\/jcp.27782","volume":"234","author":"B Farhood","year":"2019","unstructured":"Farhood B, Najafi M, Mortezaee K. CD8 + cytotoxic T lymphocytes in cancer immunotherapy: a review. J Cell Physiol. 2019;234:8509\u201321.","journal-title":"J Cell Physiol"},{"key":"1908_CR29","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.molimm.2005.03.007","volume":"43","author":"S Offner","year":"2006","unstructured":"Offner S, Hofmeister R, Romaniuk A, Kufer P, Baeuerle PA. Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells. Mol Immunol. 2006;43:763\u201371.","journal-title":"Mol Immunol"},{"key":"1908_CR30","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1517\/14712598.2015.1041373","volume":"15","author":"J Stieglmaier","year":"2015","unstructured":"Stieglmaier J, Benjamin J, Nagorsen D. Utilizing the BiTE (bispecific T-cell engager) platform for immunotherapy of cancer. Expert Opin Biol Ther. 2015;15:1093\u20139.","journal-title":"Expert Opin Biol Ther"},{"key":"1908_CR31","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/nri3845","volume":"15","author":"L Zitvogel","year":"2015","unstructured":"Zitvogel L, Galluzzi L, Kepp O, Smyth MJ, Kroemer G. Type I interferons in anticancer immunity. Nat Rev Immunol. 2015;15:405\u201314.","journal-title":"Nat Rev Immunol"},{"key":"1908_CR32","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1158\/0008-5472.CAN-03-3259","volume":"64","author":"C Blank","year":"2004","unstructured":"Blank C, et al. PD-L1\/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res. 2004;64:1140\u20135.","journal-title":"Cancer Res"},{"key":"1908_CR33","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1016\/j.celrep.2017.07.075","volume":"20","author":"M Gato-Ca\u00f1as","year":"2017","unstructured":"Gato-Ca\u00f1as M, et al. PDL1 signals through conserved sequence motifs to overcome interferon-mediated cytotoxicity. Cell Rep. 2017;20:1818\u201329.","journal-title":"Cell Rep"},{"key":"1908_CR34","doi-asserted-by":"publisher","first-page":"e1325982","DOI":"10.1080\/2162402X.2017.1325982","volume":"6","author":"JW Kleinovink","year":"2017","unstructured":"Kleinovink JW, van Hall T, Ossendorp F, Fransen MF. PD-L1 immune suppression in cancer: tumor cells or host cells? Oncoimmunology. 2017;6:e1325982.","journal-title":"Oncoimmunology"},{"key":"1908_CR35","doi-asserted-by":"publisher","first-page":"14572","DOI":"10.1038\/ncomms14572","volume":"8","author":"J Lau","year":"2017","unstructured":"Lau J, et al. Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice. Nat Commun. 2017;8:14572.","journal-title":"Nat Commun"},{"key":"1908_CR36","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1084\/jem.20160801","volume":"214","author":"VR Juneja","year":"2017","unstructured":"Juneja VR, et al. PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity. J Exp Med. 2017;214:895\u2013904.","journal-title":"J Exp Med"},{"key":"1908_CR37","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1158\/2326-6066.CIR-16-0391","volume":"5","author":"T Noguchi","year":"2017","unstructured":"Noguchi T, et al. Temporally distinct PD-L1 expression by tumor and host cells contributes to immune escape. Cancer Immunol Res. 2017;5:106\u201317.","journal-title":"Cancer Immunol Res"},{"key":"1908_CR38","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1084\/jem.20030448","volume":"198","author":"A MartIn-Fontecha","year":"2003","unstructured":"MartIn-Fontecha A, et al. Regulation of dendritic cell migration to the draining lymph node: impact on T lymphocyte traffic and priming. J Exp Med. 2003;198:615\u201321.","journal-title":"J Exp Med"},{"key":"1908_CR39","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.trecan.2018.09.001","volume":"4","author":"JP B\u00f6ttcher","year":"2018","unstructured":"B\u00f6ttcher JP, Reis e Sousa C. The role of type 1 conventional dendritic cells in cancer immunity. Trends Cancer. 2018;4:784\u201392.","journal-title":"Trends Cancer"},{"issue":"5","key":"1908_CR40","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.ccell.2017.04.003","volume":"31","author":"S Spranger","year":"2017","unstructured":"Spranger S, Dai D, Horton B, Gajewski TJ. Tumor-residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive t cell therapy. Cancer Cell. 2017;31(5):711\u201323.","journal-title":"Cancer Cell"},{"key":"1908_CR41","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.ccell.2014.09.007","volume":"26","author":"ML Broz","year":"2014","unstructured":"Broz ML, et al. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. Cancer Cell. 2014;26:638\u201352.","journal-title":"Cancer Cell"},{"key":"1908_CR42","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.ccell.2014.09.006","volume":"26","author":"B Ruffell","year":"2014","unstructured":"Ruffell B, et al. Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells. Cancer Cell. 2014;26:623\u201337.","journal-title":"Cancer Cell"},{"key":"1908_CR43","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.3389\/fimmu.2019.02215","volume":"10","author":"K Kielbassa","year":"2019","unstructured":"Kielbassa K, Vegna S, Ramirez C, Akkari L. Understanding the origin and diversity of macrophages to tailor their targeting in solid cancers. Front Immunol. 2019;10:2215.","journal-title":"Front Immunol"},{"key":"1908_CR44","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.trecan.2015.11.004","volume":"2","author":"RA Franklin","year":"2016","unstructured":"Franklin RA, Li MO. Ontogeny of tumor-associated macrophages and its implication in cancer regulation. Trends in cancer. 2016;2:20.","journal-title":"Trends in cancer"},{"key":"1908_CR45","doi-asserted-by":"publisher","first-page":"514","DOI":"10.3389\/fimmu.2014.00514","volume":"5","author":"P Italiani","year":"2014","unstructured":"Italiani P, Boraschi D. From monocytes to M1\/M2 macrophages: phenotypical vs. functional differentiation. Front Immunol. 2014;5:514.","journal-title":"Front Immunol"},{"key":"1908_CR46","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1172\/JCI31202","volume":"117","author":"TJ Curiel","year":"2007","unstructured":"Curiel TJ. Tregs and rethinking cancer immunotherapy. J Clin Invest. 2007;117:1167\u201374.","journal-title":"J Clin Invest"},{"issue":"4","key":"1908_CR47","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/nri1806","volume":"6","author":"W Zou","year":"2006","unstructured":"Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol. 2006;6(4):295\u2013307.","journal-title":"Nat Rev Immunol"},{"key":"1908_CR48","doi-asserted-by":"publisher","first-page":"7895","DOI":"10.1158\/0008-5472.CAN-09-1642","volume":"69","author":"C M\u00e9n\u00e9trier-Caux","year":"2009","unstructured":"M\u00e9n\u00e9trier-Caux C, Gobert M, Caux C. Differences in tumor regulatory T-cell localization and activation status impact patient outcome. Cancer Res. 2009;69:7895\u20138.","journal-title":"Cancer Res"},{"issue":"3","key":"1908_CR49","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1182\/blood-2006-02-002774","volume":"108","author":"M Beyer","year":"2006","unstructured":"Beyer M, Schultze JL. Regulatory T cells in cancer. Blood. 2006;108(3):804\u201311.","journal-title":"Blood"},{"key":"1908_CR50","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.immuni.2016.07.011","volume":"45","author":"A Schietinger","year":"2016","unstructured":"Schietinger A, et al. Tumor-specific T cell dysfunction is a dynamic antigen-driven differentiation program initiated early during tumorigenesis. Immunity. 2016;45:389\u2013401.","journal-title":"Immunity"},{"key":"1908_CR51","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1038\/nprot.2013.143","volume":"8","author":"FA Ran","year":"2013","unstructured":"Ran FA, et al. Genome engineering using the CRISPR-Cas9 system. Nat Protoc. 2013;8:2281\u2013308.","journal-title":"Nat Protoc"},{"key":"1908_CR52","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1084\/jem.20030323","volume":"198","author":"H Karsunky","year":"2003","unstructured":"Karsunky H, Merad M, Cozzio A, Weissman IL, Manz MG. Flt3 ligand regulates dendritic cell development from Flt3+ lymphoid and myeloid-committed progenitors to Flt3+ dendritic cells in vivo. J Exp Med. 2003;198:305\u201313.","journal-title":"J Exp Med"},{"key":"1908_CR53","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/ni.1615","volume":"9","author":"C Waskow","year":"2008","unstructured":"Waskow C, et al. The receptor tyrosine kinase Flt3 is required for dendritic cell development in peripheral lymphoid tissues. Nat Immunol. 2008;9:676\u201383.","journal-title":"Nat Immunol"},{"key":"1908_CR54","first-page":"2122","volume":"5","author":"ATL Lun","year":"2016","unstructured":"Lun ATL, McCarthy DJ, Marioni JC. A step-by-step workflow for low-level analysis of single-cell RNA-seq data with Bioconductor. F1000Research. 2016;5:2122.","journal-title":"F1000Research"},{"key":"1908_CR55","first-page":"1438","volume":"5","author":"Y Chen","year":"2016","unstructured":"Chen Y, Lun ATL, Smyth GK. From reads to genes to pathways: differential expression analysis of RNA-Seq experiments using Rsubread and the edgeR quasi-likelihood pipeline. F1000Research. 2016;5:1438.","journal-title":"F1000Research"},{"key":"1908_CR56","doi-asserted-by":"publisher","first-page":"3.11.1","DOI":"10.1002\/0471142735.im0311s72","volume":"72","author":"J Wonderlich","year":"2006","unstructured":"Wonderlich J, Shearer G, Livingstone A, Brooks A. Induction and Measurement of cytotoxic T lymphocyte activity. Curr Protoc Immunol. 2006;72:3.11.1-3.11.23.","journal-title":"Curr Protoc Immunol"},{"key":"1908_CR57","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/nmeth.3364","volume":"12","author":"DA Bolotin","year":"2015","unstructured":"Bolotin DA, et al. MiXCR: software for comprehensive adaptive immunity profiling. Nat Methods. 2015;12:380\u20131.","journal-title":"Nat Methods"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-023-01908-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-023-01908-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-023-01908-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T11:04:36Z","timestamp":1701255876000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/s12943-023-01908-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,29]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1908"],"URL":"https:\/\/doi.org\/10.1186\/s12943-023-01908-6","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,29]]},"assertion":[{"value":"13 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"NK and JT are affiliated with Orionis Biosciences NV and hold equity interests. NK and JT have no additional financial interests. The following patent applications are related to the work presented in this paper: WO\/2017\/134305, Bispecific signaling agents and uses thereof. Applicants: VIB-Ghent University and Orionis Biosciences N.V. Inventors: N.K., J.T., S.V.L., A.C. The remaining authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"191"}}